top of page
Partnering
Partnering to Build Cell Therapies That Endure
We partner with biopharma, academic teams, and developers to embed multiplex edits that make immune cells resistant to TME-driven suppression.
Our approach integrates seamlessly—strengthening your therapies without disrupting your platform.
Where We Collaborate
Cell Types
Our edits apply to αβ T, NK, and γδ T cells—preserving potency broadly
Binders
Works with CARs, TCRs, and TILs—without altering targeting
Indications
Applicable to solid or blood tumors, tuned to dominant suppressive signals.
Built to Integrate
KiraLOGIC edits are modular, programmable, and ready to embed into engineered systems—logic gates, kill switches, and more—without altering core design. This means faster integration and broader therapeutic reach.
bottom of page